Search results

The Adolescent Substance Abuse Prevention Study (ASAPS) was a randomized field trial designed to test the effectiveness of a new school-based substance abuse prevention program called Take Charge of Your Life (TCYL). The program consisted of two curricula, one for middle schools and the other for high schools, which were delivered through the Drug Abuse Resistance Education network of law enforcement officers (D.A.R.E.). TCYL was developed building on existing D.A.R.E. seventh/eighth grade and tenth/eleventh grade curricula and applied principles and strategies suggested by published literature on effective drug abuse prevention programming and effective middle and high school curricula design. ASAPS was conducted among a 2001-2002 multi-site cohort of seventh graders who were followed for five years until the 2005-2006 school year when they were in the eleventh grade. The first TCYL curriculum was delivered in the treatment schools when the students were in seventh grade and the second was delivered when they were in the ninth grade.

Over the five-year study period, the treatment and control students responded to seven self-administered surveys: (1) at baseline in the seventh grade, (2) post-intervention in the seventh grade, (3) in the eighth grade, (4) pre-intervention in the ninth grade, (5) post-intervention in the ninth grade, (6) in the tenth grade, and (7) in the eleventh grade. Topics covered by the surveys include normative beliefs, social skills, attitudes toward drug use, and self-reported use of alcohol, tobacco, marijuana, and other illicit drugs. The ASAPS data also include measures of implementation fidelity of the seventh and ninth grade TCYL curricula, which were obtained from trained observers who rated the D.A.R.E. officers' delivery in the classroom. The fidelity measures encompass content coverage and instructional strategy.

This data collection comprises two data files, both with public- and restricted-use versions. The first (the Main Data File) contains the students' survey responses and the seventh grade curriculum fidelity measures, while the second (the 9th Grade Officer Observations Data) contains the ninth grade curriculum fidelity measures.

The California Families Project (CFP) is an ongoing longitudinal study of Mexican origin families in Northern California. This study uses community, school, family, and individual characteristics to examine developmental pathways that increase risk for and resilience to drug use in Mexican-origin youth. This study also examines the impact that economic disadvantage and cultural traditions have in Mexican-origin youth. The CFP includes a community-based sample of 674 families and children of Mexican origin living in Northern California, and includes annual assessments of parents and children. Participants with Mexican surnames were drawn at random from school rosters of students during the 2006-2007 and 2007-2008 school year. Data collection included multi-method assessments of a broad range of psychological, familial, scholastic, cultural, and neighborhood factors. Initiation of the research at age 10 was designed to assess the focal children before the onset of Alcohol, Tobacco, and Other Drug (ATOD) use, thus enabling the evaluation of how hypothesized risk and resilience mechanisms operate to exacerbate early onset during adolescence or help prevent its occurrence. This study includes a diversity of families that represent a wide range of incomes, education, family history, and family structures, including two-parent and single-parent families.

The accompanying data file consists of 674 family cases with each case representing a focal child and at least one parent (Two-parent: n=549, 82 percent; Single-parent: n=125, 18 percent). Of the 3,139 total variables, 839 pertain to the focal child, 1,376 correspond to the mother, and 908 items pertain to the father.

Please note: While the California Families Project is a longitudinal study, only the baseline data are currently available in this data collection.

The Criminal Justice Drug Abuse Treatment Studies 2 (CJ-DATS 2) was launched in 2008 with a focus on conducting implementation research in criminal justice settings. NIDA's ultimate goal for CJ-DATS 2 was to identify implementation strategies that maximize the likelihood of sustained delivery of evidence-based practices to improve offender drug abuse and HIV outcomes, and to decrease their risk of incarceration.

The Medication-Assisted Therapy (MAT) study focuses on implementing linkages to medication assisted treatment in correctional settings. During the study period community corrections staff engaged in training about addiction pharmacotherapies, while leadership in the corrections and treatment facilities engage in a joint strategic planning process to identify and resolve barriers to efficient flow of clients across the two systems.

This study includes 28 datasets and over 1,400 variables. The first five datasets for this study contain data on the baseline characteristics of the treatment and corrections sites that participated in the study as well as the characteristics of the staff working at those facilities. Opinions about Medication Assisted Treatment surveys were administered to personnel at the participating corrections and treatment sites (D6). Data on Inter-organization Relations between Probation and Parole staff with Treatment Providers were also collected (DS7-DS18).

Information was extracted from the charts of clients about their alcohol and opioid dependence as well as the referrals and treatment the clients received (DS19). Probation and parole officers and treatment providers were surveyed about monthly counts of referrals (DS20-DS21).

During the study 10 staff members from the community corrections agency and local treatment providers where MAT services were available were nominated to participate in a Pharmacotherapy Exchange Council (PEC). PEC members were involved with strategic planning for implementing changes to improve the usage of Medication-Assisted Therapy. PEC members were surveyed several times throughout the study.

PEC members completed surveys on how well the sites were adhering to the Organizational Linkages Intervention (OLI) process (DS22). Community corrections staff, PEC members and Connections Coordinators in the experimental group were surveyed about their perceptions of organizational benefits and costs associated with the MATICCE intervention (DS23). The PEC rated the Connections Coordinators (DS24)and the Connections Coordinators rate the PEC (DS25). PEC researchers completed surveys on how much of the OLI was completed (DS26) as well as what the sustainability of the changes made through the MATTICE project (DS27). The final dataset provides a key for who took the KPI (Key Performance Indicators) training and who was a PEC member (DS28).

The Denver Youth Survey (DYS) is part of the larger "Program of Research on the Causes and Correlates of Delinquency" initiated by the Office of Juvenile Justice and Delinquency Prevention in 1986. The DYS is a longitudinal study of problem and successful behavior over the life course that focuses on delinquency, drug use, victimization, and mental health. The DYS is based on a probability sample of households in "high-risk" neighborhoods of Denver, Colorado. These neighborhoods were selected on the basis of their social ecology in terms of population and housing characteristics. Only socially disorganized neighborhoods with high official crime rates (top one-third) were included. The survey respondents include 1,528 children and youth who were 7, 9, 11, 13, or 15 years old in 1987, and one of their parents, who lived in one of the more than 20,000 randomly selected households.

The survey respondents include 807 boys and 721 girls and include White (10 percent), Latino (45 percent), and African American (33 percent) youth, as well as 12 percent from other racial/ethnic backgrounds. The child and youth respondents, along with one caretaker, were interviewed annually from 1988 until 1992, and annually from 1995 until 1999. The age range covered by the study is from age 7 through age 26.

The dataset contains 1,528 cases and 22,081 variables.

The Denver Youth Survey (DYS) is part of the larger "Program of Research on the Causes and Correlates of Delinquency" initiated by the Office of Juvenile Justice and Delinquency Prevention in 1986. It is a longitudinal study of problem and successful behavior over the life course that focuses on delinquency, drug use, victimization, and mental health. DYS variables also address family demographics, neighborhood characteristics, parenting, and involvement in social roles.

The DYS is based on a probability sample of households in "high-risk" neighborhoods of Denver, Colorado. These neighborhoods were selected on the basis of their social ecology in terms of population and housing characteristics. Only socially disorganized neighborhoods with high (top one-third) official crime rates were included. The survey respondents include 1,528 children and youth who were 7, 9, 11, 13, or 15 years old in 1987, and one of their parents, who lived in one of the more than 20,000 randomly selected households.

The survey respondents include 807 boys and 721 girls and include White (10%), Latino (45%), and African American (33%) youth, as well as 12% from other racial/ethnic backgrounds. The child and youth respondents, along with one caretaker, were interviewed annually from 1988 until 1992 (waves 1-5), annually from 1995 until 1999 (waves 6-10), and in 2003 (wave 11). The study covers an age range of 7 through 26.

The Detroit Neighborhood Health Study (DNHS) is a prospective, representative longitudinal cohort study of predominantly African American adults living in Detroit, Michigan. The main purpose of the study was to determine the predictive effects of ecological stressors, such as income distribution and residential segregation, on the development of post-traumatic stress disorder (PTSD), substance use, and other psychological and behavioral outcomes. An additional purpose was to study the interrelationships between ecological stressors, exposure to potentially traumatic events (PTEs), PTSD, substance use, and immune function. The study team hypothesized that exposure to ecological stressors would influence the risk of PTE exposure, PTSD, substance use, other psychological outcomes, and the relationships between these factors.

The current collection includes data from all 5 waves of the study. Cohort participants were initially recruited in 2008 with a dual-frame probability design, using telephone numbers obtained from the U.S. Postal Service Delivery Sequence Files as well as a listed-assisted random-digit-dial frame. Individuals without listed landlines or telephones and individuals with only a cell phone listed were invited to participate through a postal mail effort. Participants completed a 40 minute, structured telephone interview annually between 2008-2012 to assess perceptions of participants' neighborhoods, mental and physical health status, social support, exposure to traumatic events, and alcohol and tobacco use. In addition, the study team completed a structured assessment of Detroit's 54 neighborhoods in order to describe the characteristics of respondents' neighborhoods. The assessment included information about the quality of housing exteriors; presence of graffiti, abandoned cars, alcohol and tobacco advertisements, and security warning signs; presence of vacant buildings; and street and traffic noise levels.

All survey participants were offered the opportunity to provide a blood specimen (venipuncture, blood spot, or saliva) for immune and inflammatory marker testing as well as genetic testing of DNA. Participants received an additional $25USD if they elected to give a sample. Informed consent was obtained at the beginning of each interview and again at specimen collection. However, these specimens are not included as part of this data collection.

For more information about the study, please visit the Detroit Neighborhood Health Study website.

Genotypic data from DNHS are available on the NIH database of Genotypes and Phenotypes (dbGaP).

In the fall of 1993, the entering 1st graders in nine Baltimore City, Maryland public elementary schools were recruited for participation in a randomized trial of two universal, preventive interventions. Both interventions targeted the early antecedent risk behaviors of poor academic achievement and aggressive/coercive behavior and their distal correlates: substance abuse/dependence, antisocial behavior, high risk sexual behavior, sexually transmitted infections (STIs), and psychiatric symptoms and disorders. One intervention, the classroom-centered intervention (CC), sought to reduce the early risk behaviors of poor achievement and aggressive/coercive behaviors through the enhancement of classroom curricula and teacher instructional and behavior management practices. The second intervention, the family-school partnership intervention (FSP), sought to reduce these early risk behaviors by improving parent-teacher/school mental health professional collaboration and by enhancing parents' teaching and behavior management skills. The participating students and 1st grade teachers were randomly assigned to either the CC or FSP classroom-level conditions or to a control or standard setting classroom. The participating students' outcomes were assessed from the fall of 1st grade through 12th grade. Annual outcome assessments continued following high school through age ~ 26. Data from participating students' self-report of substance use and its putative mediators and moderators in 8th through 12th grade are available in this dataset.

The principal investigator withheld the intervention status variable that distinguishes the intervention groups from the control group. You may contact the Principal investigator to discuss obtaining the intervention variable.

This dataset contains variables on frequency of respondents' substance use during the respondents' lifetime as well as in the year, month, week prior to the survey. In addition, the dataset contains variables on alcohol consumption. The dataset also contains variables on the respondents' perceptions of the availability and harmfulness of substances. Respondents were also asked about perception of how many of his/her friends used drugs as well as their attitudes towards drug use, including personal disapproval of drug use, and perceived attitudes of parents and friends towards the respondents' drug use. Respondents were asked whether and how often they were offered substances to use and their intention to use substances if offered in the future. Substances asked about include tobacco, alcohol, marijuana, cocaine, crack, heroin, ecstasy, and inhalants.

This dataset contains 1535 variables and 713 respondents. The only demographic variables in this dataset are race and gender.

The Drug Abuse Warning Network (DAWN) is a nationally representative public health surveillance system that has monitored drug related emergency department (ED) visits to hospitals since the early 1970s. First administered by the Drug Enforcement Administration (DEA) and the National Institute on Drug Abuse (NIDA), the responsibility for DAWN now rests with the Substance Abuse and Mental Health Services Administration's (SAMHSA) Center for Behavioral Health Statistics and Quality (CBHSQ). Over the years, the exact survey methodology has been adjusted to improve the quality, reliability, and generalizability of the information produced by DAWN. The current approach was first fully implemented in the 2004 data collection year.

DAWN relies on a longitudinal probability sample of hospitals located throughout the United States. To be eligible for selection into the DAWN sample, a hospital must be a non-Federal, short-stay, general surgical and medical hospital located in the United States, with at least one 24-hour ED. DAWN cases are identified by the systematic review of ED medical records in participating hospitals. The unit of analysis is any ED visit involving recent drug use. DAWN captures both ED visits that are directly caused by drugs and those in which drugs are a contributing factor but not the direct cause of the ED visit. The reason a patient used a drug is not part of the criteria for considering a visit to be drug related. Therefore, all types of drug-related events are included: drug misuse or abuse, accidental drug ingestion, drug-related suicide attempts, malicious drug poisonings, and adverse reactions. DAWN does not report medications that are unrelated to the visit.

The DAWN public-use dataset provides information for all types of drugs, including illegal drugs, prescription drugs, over-the-counter medications, dietary supplements, anesthetic gases, substances that have psychoactive effects when inhaled, alcohol when used in combination with other drugs (all ages), and alcohol alone (only for patients aged 20 or younger). Public-use dataset variables describe and categorize up to 16 drugs contributing to the ED visit, including toxicology confirmation and route of administration. Administrative variables specify the type of case, case disposition, categorized episode time of day, and quarter of year. Metropolitan area is included for represented metropolitan areas. Created variables include the number of unique drugs reported and case-level indicators for alcohol, non-alcohol illicit substances, any pharmaceutical, non-medical use of pharmaceuticals, and all misuse and abuse of drugs. Demographic items include age category, sex, and race/ethnicity. Complex sample design and weighting variables are included to calculate various estimates of drug-related ED visits for the Nation as a whole, as well as for specific metropolitan areas, from the ED visits classified as DAWN cases in the selected hospitals.

The Drug Abuse Warning Network (DAWN) is a nationally representative public health surveillance system that has monitored drug related emergency department (ED) visits to hospitals since the early 1970s. First administered by the Drug Enforcement Administration (DEA) and the National Institute on Drug Abuse (NIDA), the responsibility for DAWN now rests with the Substance Abuse and Mental Health Services Administration's (SAMHSA) Center for Behavioral Health Statistics and Quality (CBHSQ). Over the years, the exact survey methodology has been adjusted to improve the quality, reliability, and generalizability of the information produced by DAWN. The current approach was first fully implemented in the 2004 data collection year.

DAWN relies on a longitudinal probability sample of hospitals located throughout the United States. To be eligible for selection into the DAWN sample, a hospital must be a non-Federal, short-stay, general surgical and medical hospital located in the United States, with at least one 24-hour ED. DAWN cases are identified by the systematic review of ED medical records in participating hospitals. The unit of analysis is any ED visit involving recent drug use. DAWN captures both ED visits that are directly caused by drugs and those in which drugs are a contributing factor but not the direct cause of the ED visit. The reason a patient used a drug is not part of the criteria for considering a visit to be drug related. Therefore, all types of drug-related events are included: drug misuse or abuse, accidental drug ingestion, drug-related suicide attempts, malicious drug poisonings, and adverse reactions. DAWN does not report medications that are unrelated to the visit.

The DAWN public-use dataset provides information for all types of drugs, including illegal drugs, prescription drugs, over-the-counter medications, dietary supplements, anesthetic gases, substances that have psychoactive effects when inhaled, alcohol when used in combination with other drugs (all ages), and alcohol alone (only for patients aged 20 or younger). Public-use dataset variables describe and categorize up to 16 drugs contributing to the ED visit, including toxicology confirmation and route of administration. Administrative variables specify the type of case, case disposition, categorized episode time of day, and quarter of year. Metropolitan area is included for represented metropolitan areas. Created variables include the number of unique drugs reported and case-level indicators for alcohol, non-alcohol illicit substances, any pharmaceutical, non-medical use of pharmaceuticals, and all misuse and abuse of drugs. Demographic items include age category, sex, and race/ethnicity. Complex sample design and weighting variables are included to calculate various estimates of drug-related ED visits for the Nation as a whole, as well as for specific metropolitan areas, from the ED visits classified as DAWN cases in the selected hospitals.

The Drug Abuse Warning Network (DAWN) is a nationally representative public health surveillance system that has monitored drug related emergency department (ED) visits to hospitals since the early 1970s. First administered by the Drug Enforcement Administration (DEA) and the National Institute on Drug Abuse (NIDA), the responsibility for DAWN now rests with the Substance Abuse and Mental Health Services Administration's (SAMHSA) Center for Behavioral Health Statistics and Quality (CBHSQ). Over the years, the exact survey methodology has been adjusted to improve the quality, reliability, and generalizability of the information produced by DAWN. The current approach was first fully implemented in the 2004 data collection year.

DAWN relies on a longitudinal probability sample of hospitals located throughout the United States. To be eligible for selection into the DAWN sample, a hospital must be a non-Federal, short-stay, general surgical and medical hospital located in the United States, with at least one 24-hour ED. DAWN cases are identified by the systematic review of ED medical records in participating hospitals. The unit of analysis is any ED visit involving recent drug use. DAWN captures both ED visits that are directly caused by drugs and those in which drugs are a contributing factor but not the direct cause of the ED visit. The reason a patient used a drug is not part of the criteria for considering a visit to be drug related. Therefore, all types of drug-related events are included: drug misuse or abuse, accidental drug ingestion, drug-related suicide attempts, malicious drug poisonings, and adverse reactions. DAWN does not report medications that are unrelated to the visit.

The DAWN public-use dataset provides information for all types of drugs, including illegal drugs, prescription drugs, over-the-counter medications, dietary supplements, anesthetic gases, substances that have psychoactive effects when inhaled, alcohol when used in combination with other drugs (all ages), and alcohol alone (only for patients aged 20 or younger). Public-use dataset variables describe and categorize up to 16 drugs contributing to the ED visit, including toxicology confirmation and route of administration. Administrative variables specify the type of case, case disposition, categorized episode time of day, and quarter of year. Metropolitan area is included for represented metropolitan areas. Created variables include the number of unique drugs reported and case-level indicators for alcohol, non-alcohol illicit substances, any pharmaceutical, non-medical use of pharmaceuticals, and all misuse and abuse of drugs. Demographic items include age category, sex, and race/ethnicity. Complex sample design and weighting variables are included to calculate various estimates of drug-related ED visits for the Nation as a whole, as well as for specific metropolitan areas, from the ED visits classified as DAWN cases in the selected hospitals.

The Drug Abuse Warning Network (DAWN) is a nationally representative public health surveillance system that has monitored drug related emergency department (ED) visits to hospitals since the early 1970s. First administered by the Drug Enforcement Administration (DEA) and the National Institute on Drug Abuse (NIDA), the responsibility for DAWN now rests with the Substance Abuse and Mental Health Services Administration's (SAMHSA) Center for Behavioral Health Statistics and Quality (CBHSQ). Over the years, the exact survey methodology has been adjusted to improve the quality, reliability, and generalizability of the information produced by DAWN. The current approach was first fully implemented in the 2004 data collection year.

DAWN relies on a longitudinal probability sample of hospitals located throughout the United States. To be eligible for selection into the DAWN sample, a hospital must be a non-federal, short-stay, general surgical and medical hospital located in the United States, with at least one 24-hour ED. DAWN cases are identified by the systematic review of ED medical records in participating hospitals. The unit of analysis is any ED visit involving recent drug use. DAWN captures both ED visits that are directly caused by drugs and those in which drugs are a contributing factor but not the direct cause of the ED visit. The reason a patient used a drug is not part of the criteria for considering a visit to be drug related. Therefore, all types of drug-related events are included: drug misuse or abuse, accidental drug ingestion, drug-related suicide attempts, malicious drug poisonings, and adverse reactions. DAWN does not report medications that are unrelated to the visit.

The DAWN public-use dataset provides information for all types of drugs, including illegal drugs, prescription drugs, over-the-counter medications, dietary supplements, anesthetic gases, substances that have psychoactive effects when inhaled, alcohol when used in combination with other drugs (all ages), and alcohol alone (only for patients aged 20 or younger). Public-use dataset variables describe and categorize up to 16 drugs contributing to the ED visit, including toxicology confirmation and route of administration. Administrative variables specify the type of case, case disposition, categorized episode time of day, and quarter of year. Metropolitan area is included for represented metropolitan areas. Created variables include the number of unique drugs reported and case-level indicators for alcohol, non-alcohol illicit substances, any pharmaceutical, non-medical use of pharmaceuticals, and all misuse and abuse of drugs. Demographic items include age category, sex, and race/ethnicity. Complex sample design and weighting variables are included to calculate various estimates of drug-related ED visits for the Nation as a whole, as well as for specific metropolitan areas, from the ED visits classified as DAWN cases in the selected hospitals.

The Drug Abuse Warning Network (DAWN) is a nationally representative public health surveillance system that has monitored drug related emergency department (ED) visits to hospitals since the early 1970s. First administered by the Drug Enforcement Administration (DEA) and the National Institute on Drug Abuse (NIDA), the responsibility for DAWN now rests with the Substance Abuse and Mental Health Services Administration's (SAMHSA) Center for Behavioral Health Statistics and Quality (CBHSQ). Over the years, the exact survey methodology has been adjusted to improve the quality, reliability, and generalizability of the information produced by DAWN. The current approach was first fully implemented in the 2004 data collection year.

DAWN relies on a longitudinal probability sample of hospitals located throughout the United States. To be eligible for selection into the DAWN sample, a hospital must be a non-Federal, short-stay, general surgical and medical hospital located in the United States, with at least one 24-hour ED. DAWN cases are identified by the systematic review of ED medical records in participating hospitals. The unit of analysis is any ED visit involving recent drug use. DAWN captures both ED visits that are directly caused by drugs and those in which drugs are a contributing factor but not the direct cause of the ED visit. The reason a patient used a drug is not part of the criteria for considering a visit to be drug related. Therefore, all types of drug-related events are included: drug misuse or abuse, accidental drug ingestion, drug-related suicide attempts, malicious drug poisonings, and adverse reactions. DAWN does not report medications that are unrelated to the visit.

The DAWN public-use dataset provides information for all types of drugs, including illegal drugs, prescription drugs, over-the-counter medications, dietary supplements, anesthetic gases, substances that have psychoactive effects when inhaled, alcohol when used in combination with other drugs (all ages), and alcohol alone (only for patients aged 20 or younger). Public-use dataset variables describe and categorize up to 16 drugs contributing to the ED visit, including toxicology confirmation and route of administration. Administrative variables specify the type of case, case disposition, categorized episode time of day, and quarter of year. Metropolitan area is included for represented metropolitan areas. Created variables include the number of unique drugs reported and case-level indicators for alcohol, non-alcohol illicit substances, any pharmaceutical, non-medical use of pharmaceuticals, and all misuse and abuse of drugs. Demographic items include age category, sex, and race/ethnicity. Complex sample design and weighting variables are included to calculate various estimates of drug-related ED visits for the Nation as a whole, as well as for specific metropolitan areas, from the ED visits classified as DAWN cases in the selected hospitals.

The Drug Abuse Warning Network (DAWN) is a nationally representative public health surveillance system that has monitored drug related emergency department (ED) visits to hospitals since the early 1970s. First administered by the Drug Enforcement Administration (DEA) and the National Institute on Drug Abuse (NIDA), the responsibility for DAWN now rests with the Substance Abuse and Mental Health Services Administration's (SAMHSA) Center for Behavioral Health Statistics and Quality (CBHSQ). Over the years, the exact survey methodology has been adjusted to improve the quality, reliability, and generalizability of the information produced by DAWN. The current approach was first fully implemented in the 2004 data collection year.

DAWN relies on a longitudinal probability sample of hospitals located throughout the United States. To be eligible for selection into the DAWN sample, a hospital must be a non-Federal, short-stay, general surgical and medical hospital located in the United States, with at least one 24-hour ED. DAWN cases are identified by the systematic review of ED medical records in participating hospitals. The unit of analysis is any ED visit involving recent drug use. DAWN captures both ED visits that are directly caused by drugs and those in which drugs are a contributing factor but not the direct cause of the ED visit. The reason a patient used a drug is not part of the criteria for considering a visit to be drug-related. Therefore, all types of drug-related events are included: drug misuse or abuse, accidental drug ingestion, drug-related suicide attempts, malicious drug poisonings, and adverse reactions. DAWN does not report medications that are unrelated to the visit.

The DAWN public-use dataset provides information for all types of drugs, including illegal drugs, prescription drugs, over-the-counter medications, dietary supplements, anesthetic gases, substances that have psychoactive effects when inhaled, alcohol when used in combination with other drugs (all ages), and alcohol alone (only for patients aged 20 or younger). Public-use dataset variables describe and categorize up to 22 drugs contributing to the ED visit, including toxicology confirmation and route of administration. Administrative variables specify the type of case, case disposition, categorized episode time of day, and quarter of year. Metropolitan area is included for represented metropolitan areas. Created variables include the number of unique drugs reported and case-level indicators for alcohol, non-alcohol illicit substances, any pharmaceutical, non-medical use of pharmaceuticals, and all misuse and abuse of drugs. Demographic items include age category, sex, and race/ethnicity. Complex sample design and weighting variables are included to calculate various estimates of drug-related ED visits for the Nation as a whole, as well as for specific metropolitan areas, from the ED visits classified as DAWN cases in the selected hospitals.

The Drug Abuse Warning Network (DAWN) is a nationally representative public health surveillance system that has monitored drug related emergency department (ED) visits to hospitals since the early 1970s. First administered by the Drug Enforcement Administration (DEA) and the National Institute on Drug Abuse (NIDA), the responsibility for DAWN now rests with the Substance Abuse and Mental Health Services Administration's (SAMHSA) Center for Behavioral Health Statistics and Quality (CBHSQ). Over the years, the exact survey methodology has been adjusted to improve the quality, reliability, and generalizability of the information produced by DAWN. The current approach was first fully implemented in the 2004 data collection year.

DAWN relies on a longitudinal probability sample of hospitals located throughout the United States. To be eligible for selection into the DAWN sample, a hospital must be a non-Federal, short-stay, general surgical and medical hospital located in the United States, with at least one 24-hour ED. DAWN cases are identified by the systematic review of ED medical records in participating hospitals. The unit of analysis is any ED visit involving recent drug use. DAWN captures both ED visits that are directly caused by drugs and those in which drugs are a contributing factor but not the direct cause of the ED visit. The reason a patient used a drug is not part of the criteria for considering a visit to be drug-related. Therefore, all types of drug-related events are included: drug misuse or abuse, accidental drug ingestion, drug-related suicide attempts, malicious drug poisonings, and adverse reactions. DAWN does not report medications that are unrelated to the visit.

The DAWN public-use dataset provides information for all types of drugs, including illegal drugs, prescription drugs, over-the-counter medications, dietary supplements, anesthetic gases, substances that have psychoactive effects when inhaled, alcohol when used in combination with other drugs (all ages), and alcohol alone (only for patients aged 20 or younger). Public-use dataset variables describe and categorize up to 22 drugs contributing to the ED visit, including toxicology confirmation and route of administration. Administrative variables specify the type of case, case disposition, categorized episode time of day, and quarter of year. Metropolitan area is included for represented metropolitan areas. Created variables include the number of unique drugs reported and case-level indicators for alcohol, non-alcohol illicit substances, any pharmaceutical, non-medical use of pharmaceuticals, and all misuse and abuse of drugs. Demographic items include age category, sex, and race/ethnicity. Complex sample design and weighting variables are included to calculate various estimates of drug-related ED visits for the Nation as a whole, as well as for specific metropolitan areas, from the ED visits classified as DAWN cases in the selected hospitals.

The Drug Abuse Warning Network (DAWN) is a nationally representative public health surveillance system that has monitored drug related emergency department (ED) visits to hospitals since the early 1970s. First administered by the Drug Enforcement Administration (DEA) and the National Institute on Drug Abuse (NIDA), the responsibility for DAWN now rests with the Substance Abuse and Mental Health Services Administration's (SAMHSA) Center for Behavioral Health Statistics and Quality (CBHSQ). Over the years, the exact survey methodology has been adjusted to improve the quality, reliability, and generalizability of the information produced by DAWN. The current approach was first fully implemented in the 2004 data collection year.

DAWN relies on a longitudinal probability sample of hospitals located throughout the United States. To be eligible for selection into the DAWN sample, a hospital must be a non-Federal, short-stay, general surgical and medical hospital located in the United States, with at least one 24-hour ED. DAWN cases are identified by the systematic review of ED medical records in participating hospitals. The unit of analysis is any ED visit involving recent drug use. DAWN captures both ED visits that are directly caused by drugs and those in which drugs are a contributing factor but not the direct cause of the ED visit. The reason a patient used a drug is not part of the criteria for considering a visit to be drug-related. Therefore, all types of drug-related events are included: drug misuse or abuse, accidental drug ingestion, drug-related suicide attempts, malicious drug poisonings, and adverse reactions. DAWN does not report medications that are unrelated to the visit.

The DAWN public-use dataset provides information for all types of drugs, including illegal drugs, prescription drugs, over-the-counter medications, dietary supplements, anesthetic gases, substances that have psychoactive effects when inhaled, alcohol when used in combination with other drugs (all ages), and alcohol alone (only for patients aged 20 or younger). Public-use dataset variables describe and categorize up to 22 drugs contributing to the ED visit, including toxicology confirmation and route of administration. Administrative variables specify the type of case, case disposition, categorized episode time of day, and quarter of year. Metropolitan area is included for represented metropolitan areas. Created variables include the number of unique drugs reported and case-level indicators for alcohol, non-alcohol illicit substances, any pharmaceutical, non-medical use of pharmaceuticals, and all misuse and abuse of drugs. Demographic items include age category, sex, and race/ethnicity. Complex sample design and weighting variables are included to calculate various estimates of drug-related ED visits for the Nation as a whole, as well as for specific metropolitan areas, from the ED visits classified as DAWN cases in the selected hospitals.

The Drug Use Among Young Indians: Epidemiology and Prediction study is an annual surveillance effort assessing the levels and patterns of substance use among American Indian (AI) adolescents attending schools on or near reservations. In addition to annual epidemiology of substance use, data pertaining to the normative environment for adolescent substance use were also obtained. For this data collection data comes from annual in-school surveys completed between the years 1993 to 2006, and 2009 to 2013. Students completed the surveys at school during a specified class period. The dataset contains 534 variables for 26,451 students in grades 7 to 12.

The Drug Use and Cultural Factors Among Hispanic Adolescents and Emerging Adults - Los Angeles, 2006-2016 collection examines the cultural risk and protective factors for substance use among Hispanic adolescents and emerging adults in Southern California. Adolescents were recruited in 9th grade and completed annual surveys about their substance use, acculturation, ethnic identity, cultural stressors, peer and family relationships, and cultural values. They were re-contacted to complete surveys in their early 20s; this survey also included measures of sexual behavior and interpersonal violence.

Demographic variables present in this collection include age, gender, grade in school, ethnicity, country of origin, education level, language spoken, socioeconomic status, marital status, sexual orientation, ZIP code, and place of residence.

The Flint [Michigan] Adolescent Study (FAS): A Longitudinal Follow-Up Study of Substance Use on Adult Transitional Events, 2000-2003 collection includes data collected as part of four follow-up waves conducted for the Flint Adolescent Study (FAS). These data are waves five through eight, the original four waves can be found in ICPSR study 34598 (Flint [Michigan] Adolescent Study (FAS): A Longitudinal Study of School Dropout and Substance Use, 1994-1997.)

The Flint Adolescent Study (FAS) originally interviewed 850 ninth graders in the four public high schools of Flint, MI, between 1994 and 1997. Follow-up wave interviews were conducted four years after high school, between 2000 and 2003, as participants transitioned to young adulthood. The study was conducted in collaboration with the projects of Urban and Regional Affairs and Flint Community Schools. The goal of the study was to explore the protective factors associated with school dropout and alcohol and substance use. The study followed the youths for four years beginning in the Fall of 1994 to gather the first four waves of the study. The sample reflected the overall student body in the Flint high schools. In order to study those students most at risk for leaving school before graduation, individuals with grade point averages of 3.0 and below were selected.

Interviews were conducted face-to-face with each participant in a community location. Each interview took about one hour to complete. At the end of the interview students were asked to complete the last section of the questionnaire containing questions about their drug use and sexual behavior by themselves.

Information obtained from the participants include: participation in church and community organizations; social support and influence of family and friends; self-esteem and psychological wellbeing; delinquent and violent behaviors; alcohol and substance use; sexual behavior and child bearing; school attitudes and performance; and family structure and relationships. Many items included in the follow-up waves repeat those present in the original surveys. Questions were also asked about driving behavior, stress, and racial identity. Data was also collected about participant education and occupation.

Demographic variables in this collection include age, sex, race, education, occupation, employment history, residence type, household composition, height and weight, marital status, and number of children.

Since 1982, the World Health Organization (WHO) Regional Office for Europe has sponsored a cross-national, school-based study of health-related attitudes and behaviors of young people. These studies, generally known as Health Behavior in School-Aged Children (HBSC), are based on independent national surveys of school-aged children in more than 40 participating countries. The HBSC studies were conducted every four years since the 1985-1986 school year. The data available here are from the results of the United States survey conducted during the 2009-2010 school year. The files contain data on 12,642 students from 314 participating schools. Of the 314 participating schools a school administrator questionnaire was completed by 283 of them. The study results can be used as stand-alone data, or to compare with the other countries involved in the international HBSC.

The HBSC study has two main objectives. The first objective is to monitor health-risk behaviors and attitudes in youth over time to provide background data and to identify targets for health promotion initiatives. The second objective is to provide researchers with relevant information in order to understand and explain the development of health attitudes and behaviors through early adolescence.

The study contains questions dealing with many types of drugs such as tobacco, alcohol, marijuana, and other substances. Other topics include questions about family composition, the student's physical health, and other health behaviors and attitudes. Some of these topics include eating habits, dieting, physical activity, body image, health problems, and bullying. A school administrator also completed a survey concerning the school's programs and policies that affect students' health and the content of various health courses.

The Johns Hopkins University Prevention Research center - Risks for Transitions, Baltimore city, 2008-2011 study (JHU PRC Risks for Transition in Drug Use among Urban Adults) represents data collected for a 25 years follow-up from the original JHU PRC study. At the start of the data collection, a cohort of 2,311 youth were randomly assigned to two classroom-based universal preventive interventions implemented in 43 classrooms of 19 public schools located in 5 socio-demographically distinct areas in Eastern Baltimore. This collection includes data from 1,434 respondents from the original cohort collected in 2008-2012. The mean age of the respondents was 30-32 years old.

Psychopathology (major depressive episode, phobia and anxiety disorders) was assessed using modules from the Composite International Diagnostic Interview-University of Michigan Version, CIDI- UM (WHO, 1997). An antisocial symptom scale adapted from the National Epidemiologic Survey of Alcohol and Related Conditions (NESARC) was administered which consisted of 30 questions that assessed behaviors experienced since turning 18 years of age. The alcohol, tobacco and drug modules of the interview were modeled after NESARC Alcohol Use Disorder and Associated Disabilities Interview Schedule-IV. Types of information in these modules collected include age of onset, use in past year and prior past year, frequency and recency of use, and DSM-IV abuse and dependence criteria. Socioeconomic status indicators, variables on education, employment, marital status, parenthood, social supports, family history of mental health and drug problems, general health, treatment utilization, and life events are included in this dataset.

This dataset includes 3,140 variables.